Systematic analysis and prediction for disease burden of ovarian cancer attributable to hyperglycemia: a comparative study between China and the world from 1990 to 2019

被引:4
作者
Wu, Peihong [1 ,2 ]
Jiang, Qingtao [3 ]
Han, Lei [1 ,2 ]
Liu, Xin [1 ,2 ]
机构
[1] Jiangsu Prov Ctr Dis Control & Prevent, Inst Occupat Dis Prevent, Nanjing, Peoples R China
[2] Jiangsu Prevent Med Assoc, Nanjing, Peoples R China
[3] Jiangsu Hlth Vocat Coll, Dept Clin Med, Nanjing, Peoples R China
关键词
ovarian cancer; hyperglycemia; disease burden; prediction; trend; DIABETES-MELLITUS; GLUCOSE; RISK; GROWTH;
D O I
10.3389/fmed.2023.1145487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundOvarian cancer is one of the most common female malignancies worldwide, and metabolic factors, such as hyperglycemia, are becoming potential risk factors. This study aimed to analyze the disease burden and its changing trend of ovarian cancer attributable to hyperglycemia in the Chinese population from 1990 to 2019. MethodsUsing the data released by the Global Burden of Disease study 2019 (GBD 2019), we analyze the disease burden of ovarian cancer attributable to hyperglycemia in Chinese from 1990 to 2019 via morbidity, death, disability-adjusted life years (DALY); compare it with the global population; and predict the incidence and death trend in Chinese women for the next 10 years (2020-2029). ResultsThe incidence, death cases, and DALY numbers of ovarian cancer attributable to hyperglycemia in Chinese in 2019 were 2,751, 1,758, and 44,615 person-years, respectively, with an increase of 352.5%, 356.6%, and 329.0% compared with 1990, and the growth rate was higher than the global level. The age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) in 2019 were 0.270/100,000, 0.164/100,000, and 4.103/100,000, respectively. Moreover, the average annual percent changes (AAPCs) were 2.3%, 2.0%, and 2.0%, respectively, all higher than the global average. The disease burden of ovarian cancer attributable to hyperglycemia increased with age, reaching a peak in the 45-75 age group. The prediction of the neural network model showed that the incidence and death of the disease would remain high and rise in the next 10 years. ConclusionThe disease burden caused by ovarian cancer attributable to hyperglycemia in Chinese accounts for a large proportion globally, and the ASIR, ASMR, and ASDR are increasing year by year. We should continue to pay attention to the role of metabolic factors, such as hyperglycemia, in the occurrence and development of ovarian cancer, perform a good job in tertiary prevention, and strive to reduce health losses.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Global burden of diabetes mellitus from 1990 to 2019 attributable to dietary factors: An analysis of the Global Burden of Disease Study 2019
    Hong, Ting
    Sun, Fangfang
    Wang, Qiwei
    Chen, Xufeng
    Han, Kun
    DIABETES OBESITY & METABOLISM, 2024, 26 (01) : 85 - 96
  • [22] The temporal trend of disease burden attributable to metabolic risk factors in China, 1990-2019: An analysis of the Global Burden of Disease study
    Jin, Yingzhao
    So, Ho
    Cerin, Ester
    Barnett, Anthony
    Mubarik, Sumaira
    Hezam, Kamal
    Feng, Xiaoqi
    Wang, Ziyue
    Huang, Junjie
    Zhong, Chenwen
    Hayat, Khezar
    Wang, Fang
    Wu, Ai-Min
    Xu, Suowen
    Zou, Zhiyong
    Lim, Lee-Ling
    Cai, Jiao
    Song, Yimeng
    Tam, Lai-shan
    Wu, Dongze
    FRONTIERS IN NUTRITION, 2023, 9
  • [23] Burden of Eating Disorders in China, 1990-2019: An Updated Systematic Analysis of the Global Burden of Disease Study 2019
    Li, Zhitao
    Wang, Lili
    Guan, Haixia
    Han, Cheng
    Cui, Peng
    Liu, Aihua
    Li, Yongze
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [24] The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019: An updated analysis for the Global Burden of Disease Study 2019
    Liang, Ruyi
    Feng, Xiaobing
    Shi, Da
    Yang, Meng
    Yu, Linling
    Liu, Wei
    Zhou, Min
    Wang, Xing
    Qiu, Weihong
    Fan, Lieyang
    Wang, Bin
    Chen, Weihong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (08)
  • [25] Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
    Azadnajafabad, Sina
    Moghaddam, Sahar Saeedi
    Mohammadi, Esmaeil
    Rezaei, Negar
    Rashidi, Mohammad-Mahdi
    Rezaei, Nazila H.
    Mokdad, Ali
    Naghavi, Mohsen
    Murray, Christopher J. L.
    Larijani, Bagher
    Farzadfar, Farshad
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [26] Burden of Prostate Cancer in China, 1990-2019: Findings From the 2019 Global Burden of Disease Study
    Wang, Fuquan
    Wang, Chenchen
    Xia, Haifa
    Lin, Yun
    Zhang, Dingyu
    Yin, Peng
    Yao, Shanglong
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Burden of Lung Cancer in China, 1990-2019: Findings from the Global Burden of Disease Study 2019
    Sun, Huixin
    Zhang, Haiyu
    Cai, Huilong
    Yuan, Weiguang
    Wang, Fengjiao
    Jiang, Yang
    Gu, Xinyue
    Kang, Ziman
    Kang, Yue
    CANCER CONTROL, 2023, 30
  • [28] The global burden and associated factors of ovarian cancer in 1990–2019: findings from the Global Burden of Disease Study 2019
    Shiwen Zhang
    Chen Cheng
    Zejian Lin
    Linzi Xiao
    Xin Su
    Lu Zheng
    Yingjun Mu
    Minqi Liao
    Ruiqing Ouyang
    Wanlin Li
    Junrong Ma
    Jun Cai
    Lu Liu
    Donghong Wang
    Fangfang Zeng
    Jun Liu
    BMC Public Health, 22
  • [29] Burden of Thyroid Cancer From 1990 to 2019 and Projections of Incidence and Mortality Until 2039 in China: Findings From Global Burden of Disease Study
    Cheng, Fang
    Xiao, Juan
    Shao, Chunchun
    Huang, Fengyan
    Wang, Lihua
    Ju, Yanli
    Jia, Hongying
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [30] Disease burden and attributable risk factors of lip and oral cavity cancer in China from 1990 to 2021 and its prediction to 2031
    Yu, Zhengrong
    Ma, Xiangming
    Xiao, Hanyu
    Chen, Yihong
    Wu, Yuhang
    He, Jing
    Cheng, Peiyu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12